Pregabalin Capsule
Product Images NDC 60687-484

Product Visual Gallery

This gallery contains 28 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 60687-484). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by American Health Packaging, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

100 mg Blister

Pregabalin 100 mg capsule labels from American Health Packaging. Each label shows the product name, dosage strength, dosage form, barcodes, and space for lot number and expiration date. The labels include the American Health Packaging address in Columbus, Ohio.*

FDA Label Image

100 mg Carton

Packaging label for Pregabalin Capsules, 100 mg strength, containing 100 capsules (10 x 10). The label shows the drug name Pregabalin with the dosage strength prominently displayed. It includes directions for pharmacists and storage instructions. The labeler is American Health Packaging.*

FDA Label Image

150 mg Blister

Sheet of multiple identical labels for Pregabalin 150 mg oral capsules. Each label includes the drug name, dosage form, strength, a barcode, space for expiration date and lot number, and identifies American Health Packaging, Columbus, Ohio, as the labeler.*

FDA Label Image

150 mg Carton

Pregabalin 150 mg capsules packaging label from American Health Packaging. The label indicates a package size of 100 capsules (10 x 10) for oral use, with the NDC 60687-517-01. It includes a barcode, storage instructions, usage warnings, and pharmacist guidance to dispense the medication guide with each patient.*

FDA Label Image

25 mg Blister

Packaging label for Pregabalin 25 mg oral capsules by American Health Packaging. The label includes the drug name, dosage strength, dosage form, barcode, expiration date, lot number, and manufacturer details, arranged in multiple identical blocks on a sheet.*

FDA Label Image

25 mg Carton

Label for Pregabalin Capsules 25 mg, oral dosage form, packaged in a quantity of 100 capsules (10 x 10) by American Health Packaging. The label includes the NDC 60687-473-01, barcode, pharmacist instruction to dispense a medication guide, storage conditions, and packaging information.*

FDA Label Image

50 mg Blister

Multiple identical labels for Pregabalin 50 mg oral capsules by American Health Packaging. Each label includes the product name, dosage strength, barcode, and placeholders for expiration date and lot number. Manufactured in Columbus, Ohio.*

FDA Label Image

50 mg Carton

Label for Pregabalin capsules 50 mg by American Health Packaging, featuring a 100-capsule pack count (10 x 10). The label includes the NDC 60687-484-01, a barcode, and dosing and handling instructions. It states Rx Only and advises pharmacists to dispense the Medication Guide with each patient.*

FDA Label Image

75 mg Blister

Label for Pregabalin 75 mg oral capsules. The label includes the drug name, dosage strength, dosage form, a barcode, and lot number and expiration date fields (not filled). American Health Packaging, Columbus, Ohio, is identified as the labeler. The label is repeated multiple times in a sheet format.*

FDA Label Image

75 mg Carton

Pregabalin 75 mg capsules packaging label showing 100 capsules (10 x 10) in blister form. The label includes the NDC 60687-495-01 and indicates prescription use only. It contains usage instructions for pharmacists and storage information. The product is packaged and distributed by American Health Packaging, Columbus, Ohio.*

FDA Label Image

Ahp47301

Pregabalin 25 mg oral capsule with imprint code "LA 41" on a white, oblong capsule. The image shows both sides of the capsule. Labeler is American Health Packaging.*

FDA Label Image

Ahp48401

Pregabalin 50 mg oral capsule imprinted with "LA 42" on the white capsule body, shown from two angles. The capsule is white with no additional markings visible. Labeler is American Health Packaging.*

FDA Label Image

Ahp49501

Pregabalin 50 mg oral capsules with a red and white color scheme. The capsule displays the imprint 'LA 43' on the white half. Manufactured or labeled by American Health Packaging.*

FDA Label Image

Ahp50602

Pregabalin 100 mg oral capsule shown in a red, opaque capsule form. One side of the capsule is imprinted with the code 'LA 44'. The capsule is designed for human prescription use and labeled by American Health Packaging.*

FDA Label Image

Ahp51702

Pregabalin 45 mg white capsule with imprint 'LA 45'. The capsule is shown from two angles, displaying the imprint on one side and plain white on the other. Detailed strength of 45 mg is visible; the product is an oral capsule by American Health Packaging.*

FDA Label Image

Cockcroft And Gault Equation

The image displays a formula for calculating creatinine clearance (CLCr), which includes variables for age in years, weight in kilograms, serum creatinine in mg/dL, and a factor for female patients. The formula is presented as a mathematical expression.*

FDA Label Image

Figure 1

A line chart comparing the percent of patients improved versus percent improvement in pain from baseline for Pregabalin at doses of 200 mg, 100 mg, and 25 mg taken three times a day, as well as a placebo. The chart shows different curves representing each dosage and placebo across increasing pain improvement percentages.*

FDA Label Image

Figure 10

A line chart comparing the estimated percentage of subjects without LTR over a period of 180 days for Pregabalin versus Placebo. The x-axis represents days, and the y-axis shows the estimated percentage without LTR. Pregabalin has a higher percentage of subjects without LTR throughout the period compared to Placebo.*

FDA Label Image

Figure 11

A line graph comparing percent of subjects improved in two groups, Pregabalin and Placebo, over a range of percent improved from baseline to Week 12 BOCF. The x-axis represents percent improved, and the y-axis shows percent of subjects improved, with Pregabalin showing higher improvement percentages compared to Placebo across the range.*

FDA Label Image

Figure 12

A line chart comparing the percent of subjects improved over time from baseline to week 16 for Pregabalin versus Placebo. The x-axis represents the percent improved from baseline to week 16, and the y-axis shows the percent of subjects improved. Two lines are shown: one solid line for Pregabalin and one dashed line for Placebo, indicating a higher improvement percentage with Pregabalin across the timeline.*

FDA Label Image

Figure 2

A line graph comparing the percent of patients improved versus percent improvement in pain from baseline for Pregabalin 100 mg three times a day and placebo. The graph shows two curves with Pregabalin demonstrating a higher percentage of patients improved across increasing pain improvement thresholds compared to placebo.*

FDA Label Image

Figure 3

A line graph showing the percent of patients improved versus the percent improvement in pain from baseline, comparing Pregabalin at doses of 75 mg, 150 mg, and 300 mg taken three times a day, against a placebo. The graph illustrates that higher doses of Pregabalin correspond with greater patient improvement.*

FDA Label Image

Figure 4

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline, comparing Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo. The graph shows trends in pain improvement for each treatment group.*

FDA Label Image

Figure 5

A line graph showing the percent of patients improved versus percent improvement in pain from baseline. It compares Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo in terms of patient pain improvement percentages.*

FDA Label Image

Figure 6

A bar chart showing responder rates (%) in two studies labeled E1 and E3. The x-axis lists different dose groups and placebo, while the y-axis shows response percentages. The chart compares multiple doses of pregabalin (50 mg/day to 600 mg/day) versus placebo with response rates increasing with dose.*

FDA Label Image

Figure 7

A line graph depicting seizure reduction as median percentage change from baseline versus dose (mg/day) of pregabalin. Four studies (E1 BID, E2 TID, E3 BID, E3 TID) are represented by distinct markers and lines showing increased seizure reduction with higher doses up to 600 mg/day. Significant p-values are indicated at data points.*

FDA Label Image

Figure 9

A line graph showing the percent of patients improved versus percent improvement in pain from baseline for Pregabalin at daily doses of 300 mg, 450 mg, and 600 mg, compared to placebo. The graph includes vertical reference lines at 30% and 50% improvement thresholds.*

FDA Label Image

Structure

Chemical structure of the active ingredient pregabalin, showing its molecular arrangement with amino and carboxyl functional groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.